CureVac (NASDAQ:CVAC) Sets New 52-Week High – Here’s What Happened

CureVac N.V. (NASDAQ:CVAC) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $4.19 and last traded at $4.1850, with a volume of 319314 shares changing hands. The stock had previously closed at $4.12.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of CureVac in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $6.83.

CureVac Stock Up 3.5%

The company has a market capitalization of $956.80 million, a PE ratio of 5.92 and a beta of 1.77. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.69 and a current ratio of 3.70. The stock’s 50 day moving average is $5.17 and its 200 day moving average is $5.30.

CureVac (NASDAQ:CVAC) last posted its earnings results on Monday, November 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. CureVac had a negative return on equity of 23.03% and a net margin of 199.92%.The firm had revenue of $63.53 million for the quarter, compared to the consensus estimate of $21.40 million. On average, sell-side analysts anticipate that CureVac N.V. will post 0.72 EPS for the current fiscal year.

Institutional Trading of CureVac

A number of hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its position in CureVac by 354.8% during the second quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock valued at $30,000 after acquiring an additional 4,375 shares during the last quarter. Headlands Technologies LLC purchased a new position in CureVac in the 2nd quarter worth $35,000. Integrated Wealth Concepts LLC lifted its stake in CureVac by 25.0% in the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $42,000 after purchasing an additional 3,000 shares during the last quarter. Kathmere Capital Management LLC purchased a new stake in CureVac during the second quarter valued at about $60,000. Finally, L2 Asset Management LLC bought a new position in shares of CureVac during the second quarter valued at about $70,000. Institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.